Camilla Krakstads bilde

Camilla Krakstad

  • E-postcamilla.krakstad@uib.no
  • Telefon+47 55 97 67 97+47 992 54 140
  • Besøksadresse
    Haukeland Universitetssykehus
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer? Insight into Imaging. 1-14.
  • Vis forfatter(e) (2022). Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer—time to revisit current imaging guidelines? European Radiology. 12 sider.
  • Vis forfatter(e) (2022). MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. Insight into Imaging. 1-12.
  • Vis forfatter(e) (2022). Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology. 12 sider.
  • Vis forfatter(e) (2022). Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nature Communications. 1-17.
  • Vis forfatter(e) (2022). Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers. 1-16.
  • Vis forfatter(e) (2022). APOBEC3A/B deletion polymorphism and endometrial cancer risk. Cancer Medicine.
  • Vis forfatter(e) (2021). The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology. 80-91.
  • Vis forfatter(e) (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine. 1-14.
  • Vis forfatter(e) (2021). Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. Journal of Cell Science. 1-13.
  • Vis forfatter(e) (2021). Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. American Journal of Obstetrics and Gynecology. 90.e1-90.e20.
  • Vis forfatter(e) (2021). Incorporating molecular profiling into endometrial cancer management requires prospective studies. International Journal of Gynecological Cancer.
  • Vis forfatter(e) (2021). Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American Journal of Obstetrics and Gynecology.
  • Vis forfatter(e) (2021). Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecologic Oncology. 787-794.
  • Vis forfatter(e) (2021). High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences. 17 sider.
  • Vis forfatter(e) (2021). Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 15 sider.
  • Vis forfatter(e) (2021). Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ GENOMIC MEDICINE.
  • Vis forfatter(e) (2021). Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine. 1-13.
  • Vis forfatter(e) (2021). Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 25-31.
  • Vis forfatter(e) (2021). Automated segmentation of endometrial cancer on MR images using deep learning. Scientific Reports.
  • Vis forfatter(e) (2021). An mri-based radiomic prognostic index predicts poor outcome and specific genetic alterations in endometrial cancer. Journal of Clinical Medicine. 1-11.
  • Vis forfatter(e) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 sider.
  • Vis forfatter(e) (2021). A gene signature identifying CIN3 regression and cervical cancer survival. Cancers. 1-18.
  • Vis forfatter(e) (2021). A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Vis forfatter(e) (2020). Whole-volume tumor MRI radiomics for prognostic modeling in endometrial cancer. Journal of Magnetic Resonance Imaging. 1-10.
  • Vis forfatter(e) (2020). Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer. Clinical Radiology. 1-8.
  • Vis forfatter(e) (2020). RadEx: Integrated visual exploration of multiparametric studies for radiomic tumor profiling. Computer Graphics Forum. 611-622.
  • Vis forfatter(e) (2020). Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine.
  • Vis forfatter(e) (2020). Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology. 2443-2453.
  • Vis forfatter(e) (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Vis forfatter(e) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Vis forfatter(e) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Vis forfatter(e) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Vis forfatter(e) (2019). Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer. 1037-1044.
  • Vis forfatter(e) (2019). Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • Vis forfatter(e) (2019). PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Vis forfatter(e) (2019). Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: A retrospective study. BMC Cancer. 1-8.
  • Vis forfatter(e) (2019). Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • Vis forfatter(e) (2019). Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Vis forfatter(e) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Vis forfatter(e) (2019). Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 90-98.
  • Vis forfatter(e) (2018). rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • Vis forfatter(e) (2018). Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • Vis forfatter(e) (2018). The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging. 1-14.
  • Vis forfatter(e) (2018). Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Vis forfatter(e) (2018). Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Vis forfatter(e) (2018). L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. Virchows Archiv. 591-598.
  • Vis forfatter(e) (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature Communications. 1-12.
  • Vis forfatter(e) (2018). Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Vis forfatter(e) (2018). Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine. 1978-1987.
  • Vis forfatter(e) (2018). Development of an image-guided orthotopic xenograft mouse model of endometrial cancer with controllable estrogen exposure. International Journal of Molecular Sciences. 1-16.
  • Vis forfatter(e) (2018). Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • Vis forfatter(e) (2018). Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. Journal of Pathology. 203-214.
  • Vis forfatter(e) (2018). Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Vis forfatter(e) (2017). Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
  • Vis forfatter(e) (2017). Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. OncoTarget. 109018-109026.
  • Vis forfatter(e) (2017). Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Vis forfatter(e) (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Vis forfatter(e) (2017). PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Vis forfatter(e) (2017). Increased microvascular permeability in mice lacking Epac1 (Rapgef3). Acta Physiologica. 441-452.
  • Vis forfatter(e) (2017). In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Vis forfatter(e) (2017). High visceral fat percentage is associated with poor outcome in endometrial cancer. OncoTarget. 105184-105195.
  • Vis forfatter(e) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Vis forfatter(e) (2017). Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Vis forfatter(e) (2017). Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Vis forfatter(e) (2017). Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. OncoTarget. 3881-3894.
  • Vis forfatter(e) (2017). Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Vis forfatter(e) (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • Vis forfatter(e) (2016). Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Vis forfatter(e) (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Vis forfatter(e) (2016). High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Molecular and Cellular Endocrinology. 51-57.
  • Vis forfatter(e) (2016). Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility.
  • Vis forfatter(e) (2016). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • Vis forfatter(e) (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Vis forfatter(e) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Vis forfatter(e) (2015). PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology. 1694-1703.
  • Vis forfatter(e) (2015). Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • Vis forfatter(e) (2015). Multimodal imaging of orthotopic mouse model of endometrial carcinoma. PLOS ONE. 11 sider.
  • Vis forfatter(e) (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Vis forfatter(e) (2015). Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. Gynecologic Oncology. 529-537.
  • Vis forfatter(e) (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • Vis forfatter(e) (2015). Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • Vis forfatter(e) (2015). Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • Vis forfatter(e) (2015). Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • Vis forfatter(e) (2015). Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • Vis forfatter(e) (2015). Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • Vis forfatter(e) (2015). Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer. 1863-1873.
  • Vis forfatter(e) (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Vis forfatter(e) (2014). Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Vis forfatter(e) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) (2014). Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Vis forfatter(e) (2014). Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • Vis forfatter(e) (2014). Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Vis forfatter(e) (2014). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Vis forfatter(e) (2014). Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Vis forfatter(e) (2014). Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. PLOS ONE.
  • Vis forfatter(e) (2014). Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Vis forfatter(e) (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Vis forfatter(e) (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Vis forfatter(e) (2014). Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • Vis forfatter(e) (2013). Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Vis forfatter(e) (2013). Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications - BBRC. 603-608.
  • Vis forfatter(e) (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics. 371-384.
  • Vis forfatter(e) (2013). Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Vis forfatter(e) (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
  • Vis forfatter(e) (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 sider.
  • Vis forfatter(e) (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Vis forfatter(e) (2013). High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Vis forfatter(e) (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Vis forfatter(e) (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications. 10 sider.
  • Vis forfatter(e) (2013). ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Vis forfatter(e) (2012). Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Vis forfatter(e) (2012). KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Vis forfatter(e) (2012). High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Vis forfatter(e) (2012). Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • Vis forfatter(e) (2011). Nostocyclopeptide-M1: A potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and 1B1. Molecular Pharmaceutics. 360-367.
  • Vis forfatter(e) (2011). Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death and Differentiation. 11 sider.
  • Vis forfatter(e) (2009). Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. Journal of Proteomics & Bioinformatics. 244-245.
  • Vis forfatter(e) (2008). The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Vis forfatter(e) (2008). Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Vis forfatter(e) (2006). CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Vis forfatter(e) (2004). cAMP protects neutrophils against TNF?-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). Journal of Leukocyte Biology. 641-647.
  • Vis forfatter(e) (2003). cAMP effector mechanisms. Novel twists for an "old" signaling system. FEBS Letters. 121-126.
  • Vis forfatter(e) (2003). Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chemistry and Biology. 609-618.
  • Vis forfatter(e) (2002). Ca2+/calmodulin dependent protein kinase II is required for microcystin-induced apoptosis. Journal of Biological Chemistry. 2804-2811.
Vitenskapelig foredrag
  • Vis forfatter(e) (2004). cAMP protects neutrophils against TNFa-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Vis forfatter(e) (2004). cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Vis forfatter(e) (2004). Apoptotic phenotypes induced by natural toxins - Okadaic Acid acts by short-circuiting an ancient irradiation induced death pathway.
  • Vis forfatter(e) (2003). cAMP effector mechanisms. Novel twists for an "old" signalling system.
  • Vis forfatter(e) (2002). cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Vis forfatter(e) (2001). Cell death in HeLa cells.
  • Vis forfatter(e) (1998). Distinct apoptotic death forms. Distinct pathways and functions?
  • Vis forfatter(e) (2012). Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
  • Vis forfatter(e) (2008). Quantitative proteomics of Epac signaling in differentiating human SH-SY5Y neuroblastoma cells.
  • Vis forfatter(e) (2008). Epac-induced neuronal differentiation of Human SH-SY5Y neuroblastoma cells.
  • Vis forfatter(e) (2005). Role of Cu/Zn superoxide dismutase (SOD1) in phosphatase inhibitor-induced apoptosis.
  • Vis forfatter(e) (2018). Preclinical models and molecular biomarkers. Tools to improve treatment in endometrial carcinoma.
  • Vis forfatter(e) (2017). Molecular alterations suggesting new treatment strategies in uterine carcinomas.
  • Vis forfatter(e) (2016). Hormone signaling related factors as biomarkers in endometrial cancer.
  • Vis forfatter(e) (2005). The role of CaMKII and cA-PK in control of cell survival and death.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2013). PI3K Pathway in Gynecologic Malignancies.
  • Vis forfatter(e) (2007). Serine/Threonine Protein Phosphatases in Apoptosis. 16 sider.
  • Vis forfatter(e) (2013). FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
  • Vis forfatter(e) (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Vis forfatter(e) (2010). Liver specific transporters of microcystins as a tool to find novel inhibitors of OATP1B1 and OATP1B3.
  • Vis forfatter(e) (2003). Myeloid leukemia cell differentiation by bcl-2 and camp involves induction of ccaat/enhancer binding protein ? (c/ebp?), nuclear accumulation of c/ebp?, and direct interaction between bcl-2 and c/ebp?
  • Vis forfatter(e) (2002). Effects of a new bioactive substance from a marine microalga on mammalian cells.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2021). Risk stratification of endometrial cancer patients: FIGO stage, biomarkers and molecular classification. Cancers.
  • Vis forfatter(e) (2020). Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer.
  • Vis forfatter(e) (2020). Fertility-sparing treatment in early endometrial cancer: Current state and future strategies. Obstetrics and Gynecology Science. 417-431.
  • Vis forfatter(e) (2019). Imaging of preclinical endometrial cancer models for monitoring tumor progression and response to targeted therapy. Cancers. 1-16.
  • Vis forfatter(e) (2018). Patient-derived xenograft models for endometrial cancer research. International Journal of Molecular Sciences. 1-17.
  • Vis forfatter(e) (2018). Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer. International Journal of Molecular Sciences.
  • Vis forfatter(e) (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 386-401.
  • Vis forfatter(e) (2011). The cAMP-dependent protein kinase pathway as therapeutic target - possibilities and pitfalls. Current Topics in Medicinal Chemistry. 1393-1405.
  • Vis forfatter(e) (2010). Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular Cancer. 135 .

Se fullstendig oversikt over publikasjoner i CRIStin.